[Interpretation of "Clinical practice guidelines for the treatment and prophylaxis of influenza in China (2025 edition)"].

"Clinical practice guidelines for the treatment and prophylaxis of influenza in China (2025 edition)" (hereinafter referred to as "the guideline") were jointly released by the Chinese Thoracic Society and Chinese Society of Infectious Diseases of the Chinese Medical Association. As an influenza guideline developed using evidence-based methodology in China, its key strength lies in providing systematic and actionable recommendations grounded in evidence. This article aims to provide a clinical interpretation of the guidelines, highlighting five major advancements compared with previous consensus documents: methodological innovation, stratified treatment strategies, integration of new evidence on domestically developed innovative drugs, clarification of the therapeutic window and explicit preventive strategies. This interpretation is intended to assist clinicians in thoroughly understanding the core principles and clinical considerations of the guideline, thereby promoting effective implementation.